## COR: Cencora, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.3% below STRENGTH zone (4.0-10.0%). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($326.36)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. Cencora to acquire majority stake in OneOncology for $5B**
- Source: Fierce Healthcare | 20251216T170807 | Bullish | Relevance: 100%
- Cencora is set to acquire a majority stake in OneOncology for $5 billion, accelerating its buyout of the specialty practice network. This strategic move, which values OneOncology at $7.4 billion, will see Cencora controlling the majority interest while OneOncology’s affiliated practices retain a minority share. The deal is expected to close by the end of Q1 2026 and aligns with Cencora's pharmaceutical-centric growth strategy, enhancing its distribution avenues and operational support for oncology practices.

**2. Cencora to Acquire TPG’s Equity Stake in OneOncology, Strengthening Specialty Care Platform**
- Source: Digital Health News | 20251216T110814 | Bullish | Relevance: 100%
- Cencora has announced a definitive agreement to acquire TPG's equity stake in OneOncology, a national platform supporting independent oncology practices. This acquisition is set to accelerate OneOncology's growth by expanding technology capabilities, clinical innovation, and shared services. Both Cencora and TPG expressed confidence that this move will strengthen specialty care and continue OneOncology's success in delivering accessible and innovative oncology care.

**3. Cencora stock price target raised to $420 from $400 at Evercore ISI**
- Source: Investing.com | 20251216T041012 | Bullish | Relevance: 100%
- Evercore ISI has increased its price target for Cencora Inc (NYSE:COR) to $420 from $400, while maintaining an Outperform rating. This adjustment follows Cencora's strategic acquisition of the remaining stake in OneOncology, a move anticipated to be EPS neutral initially and then positively contribute from mid-fiscal year 2027. The strong financial health and growth potential of Cencora, including robust Q4 2025 results and upward guidance revisions, have led other firms like TD Cowen, UBS, and Leerink Partners to also raise their price targets.

**4. Thurston Springer Miller Herd & Titak Inc. Decreases Position in Cencora, Inc. $COR**
- Source: MarketBeat | 20251217T142710 | Somewhat-Bullish | Relevance: 100%
- Thurston Springer Miller Herd & Titak Inc. significantly reduced its stake in Cencora, Inc. (NYSE:COR) by 93.6% in the third quarter of 2025, selling 8,838 shares and retaining 602. Despite this, analyst sentiment remains largely positive, with several firms raising price targets and the stock holding a "Moderate Buy" consensus. Cencora also reported strong Q3 earnings, beating estimates, and increased its quarterly dividend.

**5. Cencora Announces $50 Million Share Repurchase from Walgreens Boots Alliance**
- Source: MSN | 20251216T050820 | Somewhat-Bullish | Relevance: 100%
- Cencora recently announced a $50 million share repurchase from Walgreens Boots Alliance, completing a $275 million share repurchase agreement. This action maintains Cencora's commitment to returning value to shareholders and optimizing its capital structure.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $400 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 47.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+4.1%)
- Blackrock Inc.: 10.2% (+5.7%)
- JPMORGAN CHASE & CO: 4.8% (+139.5%)
- State Street Corpora: 4.7% (+9.3%)
- Price (T.Rowe) Assoc: 4.0% (-0.9%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.92 indicates undervaluation relative to growth. Quality metrics strong (ROE 124%). Balance sheet: $2.9B free cash flow. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $66.1B |
| Beta | 0.63 |
| 52W Range | $223.92 - $377.54 |
| Short Interest | 4.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.92 |
| Forward P/E | 17.5 |
| Current P/E | 19.4 |
| YoY Growth | 11.2% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.5% over 5 days). Below STRENGTH zone by 6.3pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.12x) but short-term weakness (below SMA20). MACD histogram bearish (-1.51), momentum weakening. RSI neutral at 44. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.33% (CS: 19) | Weak |
| RSI_14 | 43.5 | Neutral |
| MACD Histogram | -1.51 | Bearish |
| vs SMA20 | 0.970x | Below |
| vs SMA50 | 0.987x | Below |
| vs SMA200 | 1.125x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $340.46
- **Stop Loss:** $326.36 (4.1% risk)
- **Target:** $354.56 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 67
- **Position Value:** $22,810.82
- **Portfolio %:** 22.81%
- **Risk Dollars:** $950.00
- **Risk Per Trade:** 0.95%
- **Modifiers:** L1 95% | L2 100% | Combined 0.95x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 0.95x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with cautious positioning ahead of CPI data. VIX at moderate 16.87 with positive yield curve suggesting stable growth, but narrow breadth at 51.8% indicates selective participation. Banking sector optimism and corporate resilience provide support, though AI volatility creates pockets of uncertainty.*

### Earnings

**Next:** 2026-02-04 (Est: $4.07)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.79 | $3.84 | +1.4% |
| 2025Q2 | $3.84 | $4.00 | +4.2% |
| 2025Q1 | $4.10 | $4.42 | +7.9% |
| 2024Q4 | $3.52 | $3.73 | +6.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*